Review: Adverse Event Rate 8.8 Percent With RFA in Barrett's

This article originally appeared here.
Share this content:
Review: Adverse Event Rate 8.8 Percent With RFA in Barrett's
Review: Adverse Event Rate 8.8 Percent With RFA in Barrett's

MONDAY, July 25, 2016 (HealthDay News) -- For patients with Barrett's esophagus with dysplasia, the pooled rate of all adverse events from radiofrequency ablation (RFA) with or without endoscopic mucosal resection (EMR) is 8.8 percent, with increased risk for RFA with versus without EMR, according to a review published in the August issue of Clinical Gastroenterology and Hepatology.

Bashar J. Qumseya, M.D., from Archbold Medical Group/Florida State University in Thomasville, Ga., and colleagues conducted a systematic review and meta-analysis to examine the rate of adverse events associated with RFA with and without EMR. Data were included from 37 studies with 9,200 patients.

The researchers found that there was a pooled rate of 8.8 percent for all adverse events from RFA, with or without EMR; 5.6, 1.0, and 0.6 percent developed strictures, had bleeding, and developed a perforation, respectively. The relative risk for adverse events was significantly higher for RFA with EMR in studies that compared RFA with versus without EMR (4.4; P = 0.015). Compared with retrospective studies, prospective studies had a trend toward higher proportions of adverse events (11.3 versus 7.8 percent; P = 0.20). Barrett's esophagus length and baseline histology were also associated with adverse events.

"Endoscopists should discuss these risks with patients before endoscopic eradication therapy," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »